&lt;p&gt;Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data&lt;/p&gt;

Benucci, Maurizio; Damiani, Arianna; Gobbi, Francesca Li; Grossi, Valentina; Infantino, María; Manfredi, Mariangela; Niccoli, Laura; Cantini, Fabrizio

doi:10.2147/tcrm.s228880

Cited by 4 publications

(7 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The change in NE The main symptom of AS is pain, which is currently recognized as one type of IP [12]. Thus, previous studies and the development of new anti-AS medications have mainly focused on blocking inflammatory factors [13], [14], [15]. Given the large number of outpatients and lack of communication time between physicians and patients in China and the actual clinical situation in China, both physicians and patients usually pay attention to laboratory testing and imaging findings, inevitably leading to overlooking pain and other subjective symptoms.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of Neuropathic Pain in Ankylosing Spondylitis: Prevalence and Characteristics

Zhou

et al. 2021

Pain Ther

View full text Add to dashboard Cite

Introduction: Pain in ankylosing spondylitis is currently considered an inflammatory pain (IP). However, it was found that some patients still had the sensation of pain even without inflammation. Our study was to investigate the prevalence and characteristics of neuropathic pain (NeP) in Chinese Han ankylosing spondylitis (AS) patients. Methods: The study consisted of three parts. Firstly, we assessed the prevalence and clinical data of NeP in 182 AS patients. Secondly, we evaluated pain improvement after etanercept therapy in 63 patients. Finally, serum neurotransmitters were measured for 20 AS patients and ten healthy controls (HC).Results: Out of 182 AS patients, our study showed that 14 patients (7.70%) had likely NeP and 55 (30.21%) had uncertain NeP. There were significant differences among the three groups with respect to nocturnal pain (NP), peripheral pain (PP), total back pain (TBP), BASDAI, ASDAS-CRP, HAD-A, HAD-D, and BASDAIfatigue except fort CRP concentrations. Principal component analysis (PCA) of AS pain revealed that the weight of NeP was greater than PP in the first principal component (0.703 vs. 0.639). Structural equation modeling (SEM) revealed that NeP altered disease activity (b = 0.62, P \ 0.001), which influenced psychological status (b = 0.42, P \ 0.001). Of 63 patients who used etanercept for 3 months, significant improvement was found in NP, TBP, and PP (all P \ 0.0001) but not in PDQ (10.60 ± 6.85 vs. 9.98 ± 6.40, P = 0.0671). Serum norepinephrine concentrations in patients with PDQ [ 19 were higher than those in patients with PDQ B 19 and HC. Conclusions: We conclude that NeP contributes to pain in AS patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…These results suggested that despite the degrees of NP, TBP and PP were significantly decreased after medication administration, PDQ was not significantly decreased (mean ± SD: 10.60 ± 6.85 vs. 9.98 ± 6.40 P = 0.0671). Subgroup analysis revealed that PDQ was decreased significantly in AS patients with PDQ [ 12 (mean ± SD: 17.06 ± 2.40 vs 15…”

mentioning

confidence: 99%

Assessment of Neuropathic Pain in Ankylosing Spondylitis: Prevalence and Characteristics

Zhou

et al. 2021

Pain Ther

View full text Add to dashboard Cite

show abstract

“…Moreover, elevated serum levels of IL-17 and circulating Th17 cells have been reported in AS patients. Furthermore, endogenous interactions between IL-17A and RANKL stimulate osteoclastic activity in bone, resulting in osteoporosis, bone erosions, and osteopenia in AS patients [43,49].…”

Section: Interleukin Inhibitorsmentioning

confidence: 99%

Treatment Modalities of Ankylosing Spondylitis

Srivastava¹,

Pant²,

Srivastava³

et al. 2023

Ankylosing Spondylitis - Recent Concepts

View full text Add to dashboard Cite

Ankylosing spondylitis is a chronic inflammatory arthropathy of young adults which primarily affects the axial skeleton. The pathogenesis of AS is unclear, but it is thought to be caused by an early inflammatory phase followed by ossification that may induce local osteitis. It has also been linked to an increase in morbidity and mortality and is known to have a debilitating impact on QoL of the patients. Whereby, CRP and ESR are used for assessment of the disease activity and determination of treatment efficacy, HLA-B27 is considered the best biomarker for AS diagnosis. The conventional therapeutic regimen like NSAIDs and DMARDs alone are not effective in controlling symptoms and indicators of disease; however, when combined with the physical therapy, great improvement in the QoL of the patients has been observed. The outlook for AS has improved remarkably with the advent of biologics that blocks key inflammatory cytokines such as TNF inhibitors. Biologics aids in halting disease progression, and can be used concomitantly with other medications for pain management. In this chapter, barring surgical interventions, we will discuss about the non-pharmacological and pharmacological therapies routinely employed for the treatment of AS, as well as the novel therapeutics currently under study.

show abstract

“…Notably, ustekinumab has also demonstrated good results in uveitis (37). The incidence of anterior uveitis during treatment with ixekizumab was described; however, in several cases, patients had a pre-existing history of anterior uveitis and were HLA B27 + (38).…”

Section: Ophthalmological Changesmentioning

confidence: 99%

Psoriasis beyond the skin: Ophthalmological changes (Review)

et al. 2021

View full text Add to dashboard Cite

Psoriasis is a chronic, immune-mediated inflammatory disease of unknown etiology that may be associated with abnormal T-lymphocyte function. Ocular manifestations associated with psoriasis, particularly artropathic or pustular psoriasis, usually affect men, often during exacerbations of the disease. It has been reported that eye damage tends to occur later compared with cutaneous or joint manifestations, blindness being the most disabling complication. Previous studies have focused on ophthalmic manifestations and identified several etiopathogenic mechanisms. Psoriasis may be associated with eye complications such as lesions of the eyelids, conjunctiva and others, with systemic inflammation being the main contributor. In addition, the treatment used for psoriasis may cause ocular changes. The main ophthalmic manifestations associated with psoriasis are keratoconjunctivitis sicca, blepharitis, conjunctivitis and uveitis. The treatment of uveitis, perceived as one of the most serious eye conditions, is controversial and has yet to be clearly determined. Thus, the aim of the present review was to emphasize the importance of regular eye examination for patients with psoriasis, either those receiving biological treatment or those not receiving treatment, in order to diagnose and manage the disease appropriately.

show abstract

<p>Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data</p>

Cited by 4 publications

References 52 publications

Assessment of Neuropathic Pain in Ankylosing Spondylitis: Prevalence and Characteristics

Assessment of Neuropathic Pain in Ankylosing Spondylitis: Prevalence and Characteristics

Treatment Modalities of Ankylosing Spondylitis

Psoriasis beyond the skin: Ophthalmological changes (Review)

Contact Info

Product

Resources

About